Cyclacel Pharmaceuticals Inc. reported its first quarter financial results, showing a net loss of $0.1 million for the three months ended March 31, 2025. This is an improvement compared to a net loss of $2.9 million for the same period in 2024. The decrease in net loss includes stock-based compensation expenses of $1.6 million, up from $0.2 million in 2024. The company experienced a notable increase in general and administrative expenses, which rose by $2.6 million to $4.2 million compared to $1.6 million in the same period of the previous year. This increase was attributed to one-time costs associated with a change of control, including stock compensation expense of $1.4 million and D&O insurance costs of $0.7 million. Research and development expenses related to plogosertib decreased by $0.6 million as the company focuses on developing an alternative salt, oral formulation with improved bioavailability. A significant development was the gain on deconsolidation of the UK subsidiary, Cyclacel Limited, resulting in an increase in stockholders' equity of approximately $5.0 million. In response to a challenging economic environment and funding limitations, Cyclacel is exploring strategic alternatives such as raising additional financing or engaging in a merger or acquisition to continue as a going concern. The company has also entered into an Exchange Agreement with FITTERS Diversified Berhad to exchange shares, further indicating efforts to adapt to current business challenges.